Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).
“We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become a best-in-class MALT1 inhibitor.”
Study Design and Key Findings
The company is currently conducting a Phase 1 dose-escalation study evaluating AUR112 monotherapy in patients with relapsed/refractory lymphoid malignancies. Primary objectives include characterizing safety and identifying dose-limiting toxicities and secondary objectives include pharmacokinetics, pharmacodynamics, objective response rate, duration of response, and disease control rate.
As of the November 21, 2025 cutoff, 13 patients were evaluable for safety and 11 patients were evaluable for efficacy across three dose cohorts (100 mg, 200 mg, and 400 mg).
- Safety: AUR112 was generally well tolerated. While 84.6% of patients experienced Treatment Emergent Adverse Events (TEAEs), only 14 events in 7 patients were treatment-related. No Grade 3 or higher hyperbilirubinemia was observed, and bilirubin elevations resolved even with continued treatment. One dose-limiting toxicity (DLT) (Grade 3 neutropenia) and two DLT-equivalent events were reported.
- Pharmacokinetics/Pharmacodynamics: Drug exposure at 200 mg appears to be in the efficacious range, however further results are awaited. Pharmacodynamic data demonstrated rapid and sustained IL-2 inhibition, with all evaluated patients showing IL-2 levels below the limit of quantification by Cycle 1 Day 15.
- Efficacy: Among 11 efficacy-evaluable patients (all in 1st two cohorts), the overall response rate was 63.6%, including six partial responses and one complete response. Responses were observed in MCL, MZL, Hodgkin Lymphoma (HL), and Diffuse Large B-Cell Lymphoma (DLBCL).
Based on these encouraging results, the initiation of dose-expansion cohorts in select lymphoid malignancies, including Chronic Lymphocytic Leukemia (CLL), Waldenström’s Macroglobulinemia, MCL, and MZL are being planned.
About AUR112
AUR112 is an oral investigational MALT1 inhibitor designed to target a pivotal signaling node in the NF-κB pathway. Through highly potent and selective inhibition of MALT1, AUR112 aims to disrupt survival mechanisms that drive B-cell malignancies. In preclinical studies, AUR112 exhibited significant monotherapy activity and demonstrated a favorable safety profile.
About Aurigene Oncology Limited
Aurigene Oncology Limited, a wholly owned subsidiary of Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), is a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer. Founded in 2001, Aurigene has contributed to the discovery of 21 novel chemical entities for clinical development. Some of these molecules were in collaboration with global Pharma and biotech companies while remaining were developed on its own. Aurigene’s clinical pipeline with encouraging early clinical activity also includes first- in-class oral inhibitor of immune checkpoint protein CD47, best-in-class inhibitor of DHODH, an enzyme in the pyrimidine biosynthesis pathway and best-in-class inhibitor of acetyl transferases CBP and p300. Aurigene also has a strong pre-clinical pipeline, including advanced programs based on selective degradation of SMRACA2 (IND accepted by US-FDA), pan-KRAS, SMARCA4 and p300 discovered using its proprietary Proximity Inducer Platform (A-PROX).
For more information, please visit: www.aurigene.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251201028387/en/
© Business Wire, Inc.
Disclaimer :
هذا البيان الصحافي ليس وثيقة من إعداد وكالة فرانس برس. لن تتحمل وكالة فرانس برس أية مسؤولية تتعلق بمضمونه. ألرجاء التواصل مع الأشخاص/المؤسسات المذكورين في متن البيان الصحافي في حال كانت لديكم أية أسئلة عنه.